Market Closed -
Other stock markets
|
After market 21:00:01 | |||
154.2 EUR | -1.46% |
|
154.2 | -0.02% |
07-12 | AbbVie Submits FDA, EMA Applications for Upadacitinib to Treat Giant Cell Arteritis | MT |
07-12 | AbbVie Seeks U.S., Europe OK of Rinvoq in Giant Cell Arteritis | DJ |
Evolution of the average Target Price on AbbVie Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
![Consensus](/images/consensus_flch.gif)
Consensus detail
Consensus revision (last 18 months)
Analysts covering AbbVie Inc.
Piper Sandler | |
HSBC | |
Cantor Fitzgerald | |
Daiwa Securities | |
BMO Capital | |
Mizuho Securities | |
Barclays | |
Deutsche Bank Securities | |
UBS | |
Truist Securities | |
Morningstar | |
Wells Fargo Securities | |
Goldman Sachs | |
Raymond James | |
William Blair & Co. | |
BofA Securities | |
Morgan Stanley | |
Guggenheim | |
Argus | |
Wolfe Research | |
Atlantic Equities | |
SVB Securities LLC | |
Credit Suisse | |
Societe Generale | |
Berenberg Bank | |
JPMorgan Chase | |
Cowen | |
Redburn | |
SVB Leerink | |
RBC Capital Markets |
EPS Revisions
- Stock Market
- Equities
- ABBV Stock
- 4AB Stock
- Consensus AbbVie Inc.